NCT03499808: S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis |
|
|
| Active, not recruiting | 2 | 43 | US | Isatuximab, Hu 38SB19, SAR 650984, SAR650984, Laboratory Biomarker Analysis | SWOG Cancer Research Network, National Cancer Institute (NCI) | Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis | 12/23 | 07/25 | | |
